Current Report Filing (8-k)
September 13 2017 - 9:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 5, 2017
MEDIFAST, INC.
(Exact name of registrant as specified in
its Charter)
Delaware
|
|
001-31573
|
|
13-3714405
|
(State or other jurisdiction
|
|
(Commission file number)
|
|
(IRS Employer
|
of incorporation)
|
|
|
|
Identification No.)
|
3600 Crondall Lane, Owings Mills,
Maryland 21117
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including
area code:
(410) 581-8042
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
|
¨
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
¨
|
Item 7.01.
|
Regulation FD Disclosure.
|
Medifast, Inc. (the
“Company”) is posting an investor presentation to the Investor Relations section of the Company’s website at
https://ir.medifastnow.com/. The Company may use the investor presentation from time to time in conversations and meetings with
analysts, investors and others.
The slides used during
the presentation are furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in
this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed to be “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d)
Exhibits.
Signature
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MEDIFAST, INC.
|
|
|
|
|
|
By:
|
/s/ Jason L. Groves
|
|
|
Jason L. Groves, Esq.
Executive Vice President and General Counsel
|
|
|
|
|
|
Dated: September 13, 2017
|
|
EXHIBIT INDEX
Medifast (NYSE:MED)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medifast (NYSE:MED)
Historical Stock Chart
From Sep 2023 to Sep 2024